SCA
NBIX icon

Snowden Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Snowden Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$915K Sell
5,428
-10
-0.2% -$1.48K 0.02% 612
2026
Q1 		$716K Buy
5,438
+87
+2% +$11.5K 0.02% 650
2025
Q4 		$759K Sell
5,351
-394
-7% -$57.1K 0.02% 630
2025
Q3 		$806K Buy
5,745
+7
+0.1% +$948 0.02% 588
2025
Q2 		$721K Buy
5,738
+346
+6% +$39.7K 0.02% 626
2025
Q1 		$596K Sell
5,392
-557
-9% -$70.6K 0.02% 663
2024
Q4 		$812K Buy
5,949
+82
+1% +$10.1K 0.03% 580
2024
Q3 		$676K Sell
5,867
-4,404
-43% -$604K 0.02% 641
2024
Q2 		$1.41M Sell
10,271
-100
-1% -$13.7K 0.04% 411
2024
Q1 		$1.43M Sell
10,371
-461
-4% -$63K 0.04% 412
2023
Q4 		$1.43M Buy
10,832
+641
+6% +$73.8K 0.05% 350
2023
Q3 		$1.15M Buy
10,191
+67
+0.7% +$7.05K 0.05% 382
2023
Q2 		$955K Buy
10,124
+5,227
+107% +$511K 0.03% 469
2023
Q1 		$496K Buy
4,897
+78
+2% +$8.12K 0.02% 734
2022
Q4 		$576K Sell
4,819
-631
-12% -$73.9K 0.02% 644
2022
Q3 		$578K Buy
5,450
+1,291
+31% +$131K 0.03% 592
2022
Q2 		$405K Buy
+4,159
New +$384K 0.02% 727
2021
Q4 		– Sell
-3,717
Closed -$356K – 2099
2021
Q3 		$356K Buy
3,717
+843
+29% +$79.6K 0.02% 629
2021
Q2 		$280K Buy
+2,874
New +$275K 0.01% 735

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Snowden Capital Advisors's NBIX Position: Q2 2026 in Review

Snowden Capital Advisors reduced its Neurocrine Biosciences (NBIX) stake by 0.18% in Q2 2026, selling an estimated $1.48K and leaving 5,428 shares worth $915K. The position accounts for 0.02% of the portfolio, ranked #612.

Snowden Capital Advisors first reported a position in NBIX in Q2 2021 and has held it in 19 quarters since. The position peaked at $1.43M in Q1 2024. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Snowden Capital Advisors held 5,428 shares of Neurocrine Biosciences worth $915K as of Q2 2026.
  • Snowden Capital Advisors sold 10 Neurocrine Biosciences shares in Q2 2026, an estimated $1.48K.
  • Neurocrine Biosciences made up 0.02% of Snowden Capital Advisors's portfolio in Q2 2026, its #612 holding.
  • Snowden Capital Advisors first reported a position in Neurocrine Biosciences in Q2 2021 and has held it in 19 quarters since.
  • Snowden Capital Advisors's Neurocrine Biosciences position peaked at $1.43M in Q1 2024.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.